Condition
Astrocytoma, IDH-Mutant, Grade 2
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Active Not Recruiting1
Suspended1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06860594Phase 1SuspendedPrimary
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT03528642Phase 1Active Not RecruitingPrimary
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
NCT05303519Phase 3Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Showing all 3 trials